Abstract:The development of next-generation sequencing technology and the discovery of specific antibodies targeting chemically modified nucleotides have paved the way for a new era of epitranscriptomics. Cellular RNA is known to dynamically and reversibly undergo different chemical modifications after transcription, such as N<a class="workspace-trigger" href="#bib6">6</a>-methyladenosine (m6A), N<a class="workspace-trigger" href="#bib1">1</a>-methyladenosine (m1A), N<a class="workspace-trigger" href="#bib6">6</a>,2'-O-dimethyladenosine (m6Am), 5-methylcytosine (m5C), and 5-hydroxymethylcytidine (hm<a class="workspace-trigger" href="#bib5">5</a>C), whose identity and location comprise the field of epitranscriptomics. Dynamic post-transcriptional modifications determine the fate of target RNAs by regulating various aspects of their processing, including RNA export, transcript processing, splicing, and degradation. The most abundant internal mRNA modification in eukaryotic cells is m6A, which exhibits essential roles in physiological processes, such as embryogenesis, carcinogenesis, and neurogenesis. m6A is deposited by the m6A methyltransferase complex (composed of METTL3/14/16, WTAP, KIAA1429, and RBM15/15B), erased by demethylases (FTO and ALKBH5), and recognized by binding proteins (e.g., YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3). Liver is the largest digestive and metabolic organ, and m6A modifications play unique roles in critical physiological hepatic functions and various liver diseases. This review focuses on the biological roles of m6A RNA methylation in lipid metabolism, viral hepatitis, nonalcoholic fatty liver disease, liver cancer, and tumor metastasis. In addition, we summarize the existing inhibitors targeting m6A regulators and discuss the potential of modulating m6A modifications as a therapeutic strategy.

Research Progress of mRNA Modification in Chronic Liver Disease

N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment

Epitranscriptomics in liver disease: Basic concepts and therapeutic potential

The role of N6-methyladenosine modification in the life cycle and disease pathogenesis of hepatitis B and C viruses

RNA modifications in the progression of liver diseases: from fatty liver to cancer

Decoding m6A mRNA methylation by reader proteins in liver diseases

The impact of epitranscriptomic modifications on liver disease

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Dysregulated N6-methyladenosine (m6A) processing in hepatocellular carcinoma

RNA m6A methylation regulators in liver cancer

[Research progress on regulation of N6-adenylate methylation modification in lipid metabolism disorders]

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

Roles of N6‐methyladenosine epitranscriptome in non‐alcoholic fatty liver disease and hepatocellular carcinoma

The Roles of M6a RNA Modifiers in Human Cancer

Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.

[Research progress on the role of N6-methyladenosine methylation in the pathogenesis and development of respiratory diseases]

New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma

The emerging roles of m6A modification in liver carcinogenesis

Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer

Progress in Epigenetic Modification of Mrna and the Function of M6a Modification

The role of m6A modification in physiology and disease